Literature DB >> 29985049

Intestinal homeostasis is restored in mice following a period of intestinal growth induced by orally administered Emu Oil.

Suzanne Mashtoub1,2,3, Ker Y Cheah2, Kerry A Lymn4, Gordon S Howarth2,3,4.   

Abstract

Previously, we reported that orally administered Emu Oil (EO) increases mucosal thickness in the small intestine and colon in rodent models of chemotherapy-induced mucositis and colitis. However, it remains unclear whether mucosal thickening (crypt and villus lengthening) represents a process of normal or aberrant growth. We sought to determine if villus height (VH) and crypt depth (CD) measurements returned to normal in EO-treated rats following withdrawal of EO therapy. Dark agouti rats ( n = 8/group) were gavaged daily for 10 days with water, olive oil (OO), or EO (0.5 mL or 1 mL). Groups of rats were euthanized on days 10 and 17. Intestinal weights, lengths, VH, and CD were quantified. P < 0.05 was considered significant. On day 10, jejuno-ileum weight was increased by OO (26%) and EO (0.5 mL: 15%; 1 mL: 29%) compared to water controls ( P < 0.01), which was normalized by day 17. On days 10 and 17, jejuno-ileum length was greater in OO- (12%) and EO-treated rats (0.5 mL: 8%; 1 mL: 12%; P < 0.05), relative to water controls. On day 10, OO and EO increased ileal VH (OO: 32%; 0.5 EO: 22%; EO: 35%; P < 0.01) and CD (OO: 17%; 0.5 EO: 13%; EO: 22%) compared to water controls. Importantly, however, after withdrawal of all oils, VH and CD measurements returned to normal control values. Moreover, the VH:CD ratio (potential indicator of dysplasia) remained unchanged in all experimental groups on days 10 and 17. The restoration of normal intestinal architecture following cessation of Emu Oil therapy supports its safety for application in intestinal disorders. Impact statement Uncontrolled inflammation and intestinal proliferation can predispose to the development of colorectal cancer. In previous pre-clinical studies, we demonstrated that oral administration of Emu Oil promotes intestinal repair via stimulation of the mucosa in response to tissue injury and inflammation. Therefore, it was important to determine if Emu Oil administration did not promote the precocious development of colorectal cancer. The current study revealed that Emu Oil returned indicators of intestinal proliferation back to normal values after a period of seven days. These data strongly support the safety of Emu Oil for further studies in the context of bowel inflammation.

Entities:  

Keywords:  Emu Oil; dark agouti rats; intestinal mucosa

Mesh:

Substances:

Year:  2018        PMID: 29985049      PMCID: PMC6108051          DOI: 10.1177/1535370218787457

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  28 in total

1.  Influence of two dietary fats on the composition of emu oil and meat.

Authors:  L M Beckerbauer; R Thiel-Cooper; D U Ahn; J L Sell; F C Parrish; D C Beitz
Journal:  Poult Sci       Date:  2001-02       Impact factor: 3.352

2.  Conjugated linoleic acid stimulates an anti-tumorigenic protein NAG-1 in an isomer specific manner.

Authors:  Seong-Ho Lee; Kiyoshi Yamaguchi; Jong-Sik Kim; Thomas E Eling; Stephen Safe; Yeonhwa Park; Seung Joon Baek
Journal:  Carcinogenesis       Date:  2005-11-14       Impact factor: 4.944

3.  Mechanisms of omega-3 fatty acid-induced growth inhibition in MDA-MB-231 human breast cancer cells.

Authors:  Patricia D Schley; Humberto B Jijon; Lindsay E Robinson; Catherine J Field
Journal:  Breast Cancer Res Treat       Date:  2005-07       Impact factor: 4.872

4.  Emu Oil Improves Clinical Indicators of Disease in a Mouse Model of Colitis-Associated Colorectal Cancer.

Authors:  Lauren C Chartier; Gordon S Howarth; Ian C Lawrance; Debbie Trinder; Scott J Barker; Suzanne Mashtoub
Journal:  Dig Dis Sci       Date:  2017-12-06       Impact factor: 3.199

5.  Differential induction of apoptosis and inhibition of the PI3-kinase pathway by saturated, monounsaturated and polyunsaturated fatty acids in a colon cancer cell model.

Authors:  Anna-Mart Engelbrecht; Joe-Lin du Toit-Kohn; Beverly Ellis; Mark Thomas; Theo Nell; Rob Smith
Journal:  Apoptosis       Date:  2008-11       Impact factor: 4.677

6.  Emu Oil Combined with Lyprinol™ Reduces Small Intestinal Damage in a Rat Model of Chemotherapy-Induced Mucositis.

Authors:  Suzanne Mashtoub; Lorrinne S Lampton; Georgina L Eden; Ker Y Cheah; Kerry A Lymn; Juliana E Bajic; Gordon S Howarth
Journal:  Nutr Cancer       Date:  2016-08-11       Impact factor: 2.900

7.  Docosahexaenoic acid (DHA), a primary tumor suppressive omega-3 fatty acid, inhibits growth of colorectal cancer independent of p53 mutational status.

Authors:  Taeko Kato; Nicole Kolenic; Ronald S Pardini
Journal:  Nutr Cancer       Date:  2007       Impact factor: 2.900

8.  N-3 PUFAs have antiproliferative and apoptotic effects on human colorectal cancer stem-like cells in vitro.

Authors:  Ting Yang; Shi Fang; Hai-Xia Zhang; Li-Xiao Xu; Zhan-Qiang Zhang; Kai-Tao Yuan; Cong-Long Xue; Hong-Lan Yu; Sheng Zhang; Yu-Fei Li; Han-Ping Shi; Yan Zhang
Journal:  J Nutr Biochem       Date:  2012-07-31       Impact factor: 6.048

9.  Effects of full-length and truncated insulin-like growth factor-I on nitrogen balance and muscle protein metabolism in nitrogen-restricted rats.

Authors:  F M Tomas; S E Knowles; P C Owens; L C Read; C S Chandler; S E Gargosky; F J Ballard
Journal:  J Endocrinol       Date:  1991-01       Impact factor: 4.286

10.  Emu oil reduces small intestinal inflammation in the absence of clinical improvement in a rat model of indomethacin-induced enteropathy.

Authors:  Suzanne M Abimosleh; Cuong D Tran; Gordon S Howarth
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-14       Impact factor: 2.629

View more
  1 in total

1.  Orally administered emu oil attenuates disease in a mouse model of Crohn's-like colitis.

Authors:  Chloe J Mitchell; Gordon S Howarth; Lauren C Chartier; Debbie Trinder; Ian C Lawrance; Li San Huang; Suzanne Mashtoub
Journal:  Exp Biol Med (Maywood)       Date:  2020-09-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.